Citi analyst Geoff Meacham raised the firm’s price target on Pfizer (PFE) to $26 from $25 and keeps a Neutral rating on the shares. The company reported strong Q2 results but policy headwinds warrant a continued cautious stance, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE: